We are analyzing https://link.springer.com/article/10.1007/s40264-013-0050-x.

Title:
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy | Drug Safety
Description:
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic effects on various organs such as the heart, lungs, liver, kidneys, thyroid, skin, blood coagulation, gastrointestinal tract and nervous system. Many of these toxic effects result from downstream inhibition of vascular endothelial growth factor or epidermal growth factor signalling in cells of normal organs. Many of these undesirable effects such as hypertension, hypothyroidism, skin reactions and possibly proteinuria are on-target effects. Since tyrosine kinases are widely distributed with specific functional roles in different organs, this association is not too surprising. Various studies suggest that the development of these on-target effects indicates clinically desirable and effective inhibition of the corresponding ligand-mediated receptor linked with oncogenesis. This is reflected as improved efficacy in the subgroup of patients who develop these on-target adverse effects compared with those who do not. Inevitably, issues arise with respect to the regulatory assessment of efficacy and risk/benefit of the TKIs as well as the clinical approach to managing patients who develop these effects. Routine subgroup analysis of efficacy data from clinical trials (patients with and without on-target toxicity) may enable more effective clinical use of TKIs since (i) discontinuing or reducing the dose of the TKI has a negative impact if the tumour is TKI-responsive; and (ii) it is usually possible to manage these undesirable on-target effects with conventional clinical approaches. Prospective studies are needed to investigate this proposition further.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, google, scholar, pubmed, cas, cancer, patients, clin, inhibitors, url, accessed, oct, tyrosine, clinical, kinase, oncol, fda, skin, factor, receptor, label, approved, thyroid, growth, sunitinib, treated, efficacy, shah, rash, treatment, hypertension, hypothyroidism, cell, effects, renal, management, inhibitor, res, httpwwwaccessdatafdagovdrugsatfdadocslabelslblpdf, erlotinib, carcinoma, lung, epidermal, advanced, vegf, sorafenib, safety, ontarget, toxicities, inhibition,

Topics {✒️}

protocolid=115227&studyid=7fe7fadd-d3fa-4bd6-9bf5-0845ff2a2c90&compound=pazopanib&type=compound&letterrange=l gov/ohrms/dockets/ac/02/briefing/3894b1_03_fda-medical%20officer%20review eu/docs/en_gb/document_library/epar_-_scientific_discussion/human/000690/wc500027707 eu/docs/en_gb/document_library/epar_-_public_assessment_report/human/001141/wc500094275 eu/docs/en_gb/document_library/epar_-_public_assessment_report/human/001016/wc500036361 gov/drugsatfda_docs/label/2012/022465s-010s-012lbl epidermal-growth-factor-receptor egfr-inhibitor-induced skin reactions tyrosine-kinase selective inhibitor ligand-mediated receptor linked month download article/chapter 3-amino-1h-indazol-4-yl small-cell lung cancer chemotherapy-induced iatrogenic injury gov/drugsatfda_docs/nda/2012/202324orig1s000clinpharmr gov/drugsatfda_docs/label/2012/202324lbl gov/drugsatfda_docs/label/2012/203341lbl gov/drugsatfda_docs/label/2012/202570s003lbl gov/drugsatfda_docs/label/2011/021986s009s010lbl gov/drugsatfda_docs/label/2012/021743s017lbl gov/drugsatfda_docs/label/2005/021399s008lbl gov/drugsatfda_docs/label/2012/021588s035lbl gov/drugsatfda_docs/label/2012/022059s013lbl gov/drugsatfda_docs/label/2012/022068s012lbl gov/drugsatfda_docs/label/2012/203085lbl gov/drugsatfda_docs/label/2012/202192s001lbl gov/drugsatfda_docs/label/2011/021923s012lbl gov/drugsatfda_docs/label/2012/021938s019s020lbl gov/drugsatfda_docs/label/2011/022405s001lbl gov/drugsatfda_docs/label/2011/202429s000lbl tyrosine kinase inhibitors angiogenesis inhibitor-treated patients tyrosine kinase signalling renal thrombotic microangiopathy renal cell carcinoma literature-based meta-analysis european medicines agency renal carcinoma treated phosphatase inhibitor menadione targeted therapies tumor growth inhibition independent prognostic factor targeted therapy rini bi privacy choices/manage cookies van etten ra van der veldt noncardiac vascular toxicities managing skin reactions european economic area

Questions {❓}

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
         description:Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic effects on various organs such as the heart, lungs, liver, kidneys, thyroid, skin, blood coagulation, gastrointestinal tract and nervous system. Many of these toxic effects result from downstream inhibition of vascular endothelial growth factor or epidermal growth factor signalling in cells of normal organs. Many of these undesirable effects such as hypertension, hypothyroidism, skin reactions and possibly proteinuria are on-target effects. Since tyrosine kinases are widely distributed with specific functional roles in different organs, this association is not too surprising. Various studies suggest that the development of these on-target effects indicates clinically desirable and effective inhibition of the corresponding ligand-mediated receptor linked with oncogenesis. This is reflected as improved efficacy in the subgroup of patients who develop these on-target adverse effects compared with those who do not. Inevitably, issues arise with respect to the regulatory assessment of efficacy and risk/benefit of the TKIs as well as the clinical approach to managing patients who develop these effects. Routine subgroup analysis of efficacy data from clinical trials (patients with and without on-target toxicity) may enable more effective clinical use of TKIs since (i) discontinuing or reducing the dose of the TKI has a negative impact if the tumour is TKI-responsive; and (ii) it is usually possible to manage these undesirable on-target effects with conventional clinical approaches. Prospective studies are needed to investigate this proposition further.
         datePublished:2013-04-26T00:00:00Z
         dateModified:2013-04-26T00:00:00Z
         pageStart:413
         pageEnd:426
         sameAs:https://doi.org/10.1007/s40264-013-0050-x
         keywords:
            Overall Survival
            Hypothyroidism
            Sorafenib
            Sunitinib
            Gefitinib
            Drug Safety and Pharmacovigilance
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Drug Safety
            issn:
               1179-1942
               0114-5916
            volumeNumber:36
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing AG
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Devron R. Shah
               affiliation:
                     name:Rashmi Shah Consultancy Ltd
                     address:
                        name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rashmi R. Shah
               affiliation:
                     name:Rashmi Shah Consultancy Ltd
                     address:
                        name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Joel Morganroth
               affiliation:
                     name:eResearch Technology
                     address:
                        name:eResearch Technology, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
      description:Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic effects on various organs such as the heart, lungs, liver, kidneys, thyroid, skin, blood coagulation, gastrointestinal tract and nervous system. Many of these toxic effects result from downstream inhibition of vascular endothelial growth factor or epidermal growth factor signalling in cells of normal organs. Many of these undesirable effects such as hypertension, hypothyroidism, skin reactions and possibly proteinuria are on-target effects. Since tyrosine kinases are widely distributed with specific functional roles in different organs, this association is not too surprising. Various studies suggest that the development of these on-target effects indicates clinically desirable and effective inhibition of the corresponding ligand-mediated receptor linked with oncogenesis. This is reflected as improved efficacy in the subgroup of patients who develop these on-target adverse effects compared with those who do not. Inevitably, issues arise with respect to the regulatory assessment of efficacy and risk/benefit of the TKIs as well as the clinical approach to managing patients who develop these effects. Routine subgroup analysis of efficacy data from clinical trials (patients with and without on-target toxicity) may enable more effective clinical use of TKIs since (i) discontinuing or reducing the dose of the TKI has a negative impact if the tumour is TKI-responsive; and (ii) it is usually possible to manage these undesirable on-target effects with conventional clinical approaches. Prospective studies are needed to investigate this proposition further.
      datePublished:2013-04-26T00:00:00Z
      dateModified:2013-04-26T00:00:00Z
      pageStart:413
      pageEnd:426
      sameAs:https://doi.org/10.1007/s40264-013-0050-x
      keywords:
         Overall Survival
         Hypothyroidism
         Sorafenib
         Sunitinib
         Gefitinib
         Drug Safety and Pharmacovigilance
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Drug Safety
         issn:
            1179-1942
            0114-5916
         volumeNumber:36
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing AG
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Devron R. Shah
            affiliation:
                  name:Rashmi Shah Consultancy Ltd
                  address:
                     name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rashmi R. Shah
            affiliation:
                  name:Rashmi Shah Consultancy Ltd
                  address:
                     name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Joel Morganroth
            affiliation:
                  name:eResearch Technology
                  address:
                     name:eResearch Technology, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Drug Safety
      issn:
         1179-1942
         0114-5916
      volumeNumber:36
Organization:
      name:Springer International Publishing AG
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Rashmi Shah Consultancy Ltd
      address:
         name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
         type:PostalAddress
      name:Rashmi Shah Consultancy Ltd
      address:
         name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
         type:PostalAddress
      name:eResearch Technology
      address:
         name:eResearch Technology, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Devron R. Shah
      affiliation:
            name:Rashmi Shah Consultancy Ltd
            address:
               name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
               type:PostalAddress
            type:Organization
      name:Rashmi R. Shah
      affiliation:
            name:Rashmi Shah Consultancy Ltd
            address:
               name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Joel Morganroth
      affiliation:
            name:eResearch Technology
            address:
               name:eResearch Technology, Philadelphia, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
      name:Rashmi Shah Consultancy Ltd, Buckinghamshire, UK
      name:eResearch Technology, Philadelphia, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(285)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.3s.

LINK . SPRINGER . COM {}